Drug Profile
Paclitaxel-eluting balloon catheter - MEDRAD
Alternative Names: CotavanceLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator MEDRAD
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Immunosuppressants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Peripheral arterial occlusive disorders
Most Recent Events
- 05 Nov 2014 Efficacy data from a phase I/II trial in Peripheral arterial occlusive disorders released by Covidien
- 04 Nov 2014 Adverse events data from a phase I/II trial in Peripheral arterial occlusive disorders released by Covidien
- 01 May 2014 Covidien and MEDRAD complete the phase I/II DEFINITIVE AR trial in Peripheral arterial occlusive disorders in Europe (NCT01366482)